These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 37222135)

  • 41. Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression.
    Sumarni U; Zhu J; Sinnberg T; Eberle J
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic apoptotic effect of Mcl-1 inhibition and doxorubicin on B-cell precursor acute lymphoblastic leukemia cells.
    Ebrahimi E; Shabestari RM; Bashash D; Safa M
    Mol Biol Rep; 2022 Mar; 49(3):2025-2036. PubMed ID: 35138523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
    Erdogdu U; Dolgikh N; Laszig S; Särchen V; Meister MT; Wanior M; Knapp S; Boedicker C
    Neoplasia; 2022 Feb; 24(2):109-119. PubMed ID: 34959030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
    Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
    Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1.
    Yakymiv Y; Augeri S; Bracci C; Marchisio S; Aydin S; D'Ardia S; Massaia M; Ferrero E; Ortolan E; Funaro A
    Sci Rep; 2021 Oct; 11(1):21230. PubMed ID: 34707185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
    Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
    Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
    Cell Death Dis; 2014 Feb; 5(2):e1072. PubMed ID: 24556687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
    S Soderquist R; Eastman A
    Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA.
    Mallick DJ; Eastman A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.
    Okamoto T; Coultas L; Metcalf D; van Delft MF; Glaser SP; Takiguchi M; Strasser A; Bouillet P; Adams JM; Huang DC
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):261-6. PubMed ID: 24363325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.
    Chiou JT; Lee YC; Wang LJ; Chang LS
    Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.